SERA PROGNOSTICS, INC. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sera Prognostics, Inc. on June 25, 2026. The report discloses the appointment of a new director to the Board of Directors, effective July 1, 2026.
Key Financial Metrics
The filing does not provide financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change is the appointment of Mark Capone as a Class II director and member of the Compensation Committee. Mr. Capone brings over 40 years of experience in molecular diagnostics and biotechnology, including a previous tenure as CEO of Myriad Genetics.
Guidance, Outlook, and Compensation Details
The filing outlines the compensatory arrangements for Mr. Capone under the Company's Non-Employee Director Compensation Policy:
- Initial Grant: On July 10, 2026, Mr. Capone will receive an equity award with a grant date fair value of $167,072 (or 150,000 option equivalents, whichever is lesser), split between stock options and restricted stock units (RSUs).
- Vesting Schedule: RSUs vest in three annual installments; options vest in 36 monthly installments.
- Annual Grant: Following each annual meeting, he is entitled to an equity award with a grant date fair value of $88,359 (or 75,000 option equivalents, whichever is lesser).
- Annual Vesting: Annual RSUs vest in one installment; annual options vest in 12 monthly installments.
- Cash Compensation: Mr. Capone will receive standard cash compensation for Board and Committee service.
The Board has determined Mr. Capone is an independent director. No forward-looking financial guidance or risk factors specific to operations were disclosed in this filing.
Investor Verification Checklist
- Verify the full text of the Non-Employee Director Compensation Policy (Exhibit 10.1) to confirm cash compensation amounts and specific vesting conditions.
- Review the press release dated June 30, 2026 (Exhibit 99.1) for additional context on the appointment.
- Confirm the impact of the new director on the composition of the Compensation Committee and Audit Committee.
- Check subsequent filings for any changes to the equity grant values based on stock price fluctuations prior to the grant date.